HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Advanced stage thymomas and thymic carcinomas: results of multimodality treatments.

AbstractBACKGROUND:
With the aim of evaluating the results of multidisciplinary approaches, we reviewed our experience in multimodality treatment of advanced stage (III and IVA) thymic tumors.
METHODS:
From 1976 to 2003, 56 patients with Masaoka stage III and IVA thymic tumors underwent a multimodality treatment. Thirty-six patients underwent neoadjuvant chemotherapy, surgery, and postoperative radiotherapy; 20 patients were treated by primary surgery and postoperative radiotherapy (n = 12), chemotherapy (n = 1) or chemoradiotherapy (n = 7). The neoadjuvant or adjuvant chemotherapy consisted of three courses of cisplatin, epidoxorubicin, and etoposide every 3 weeks. Adjuvant radiotherapy consisted of 45 Gy for complete resections or 60 Gy for incomplete resections.
RESULTS:
The preoperative diagnosis of invasive thymomas was performed in a total of 29 cases: 15 by mediastinotomy, 6 by video-assisted thoracoscopic surgery, and 8 by fine-needle aspiration. In 27 cases no diagnosis was available, but in most of them a thymus-related syndrome was present. Thirty-four patients are still alive (31 disease-free), and 22 have died (2 disease-free). Ten-year survival was 48% and 45.7% for stage III and IVA thymomas, respectively. The presence of myasthenia gravis (p = 0.04) and neoadjuvant chemotherapy (p = 0.004) affected survival significantly.
CONCLUSIONS:
The multimodality treatment of stage III and IVA thymic tumors allows a good long-term outcome; the neoadjuvant chemotherapy improves the resectability rate and the survival of both stages of the disease.
AuthorsMarco Lucchi, Marcello Carlo Ambrogi, Leonardo Duranti, Fulvio Basolo, Gabriella Fontanini, Carlo Alberto Angeletti, Alfredo Mussi
JournalThe Annals of thoracic surgery (Ann Thorac Surg) Vol. 79 Issue 6 Pg. 1840-4 (Jun 2005) ISSN: 1552-6259 [Electronic] Netherlands
PMID15919267 (Publication Type: Journal Article)
Chemical References
  • Epirubicin
  • Etoposide
  • Cisplatin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carcinoma (drug therapy, pathology, radiotherapy, surgery)
  • Cisplatin (administration & dosage)
  • Combined Modality Therapy
  • Epirubicin (administration & dosage)
  • Etoposide (administration & dosage)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myasthenia Gravis (complications)
  • Neoadjuvant Therapy
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Survival Analysis
  • Thymoma (drug therapy, pathology, radiotherapy, surgery)
  • Thymus Neoplasms (drug therapy, pathology, radiotherapy, surgery)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: